SCHEMBL2843649

SCHEMBL2843649

Cc1nccn1-c1ccc(Nc2nc3c(c(NCC4CCOCC4)n2)CN(C(=O)OC(C)(C)C)CC3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.47
MAPT P10636 1/20 0.42
MTOR P42345 3/20 0.42
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
PTK2 Q05397 1/20 0.40
TRPV1 Q8NER1 3/20 0.40
RAF1 P04049 1/20 0.40
BRAF P15056 1/20 0.40
CCND3 P30281 2/20 0.38
CCNK O75909 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CDK9 P50750 1/20 0.38
CDK6 Q00534 1/20 0.38
TGFBR1 P36897 1/20 0.37
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
CCND2 P30279 1/20 0.37
MERTK Q12866 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2447374 0.90 SYK (0.41) SYKJAK2JAK3TRPV1FLT3
SCHEMBL2477999 0.90 TNK2 (0.43) SYKMAPTMTORJAK2TRPV1
SCHEMBL2478002 0.90 TNK2 (0.43) SYKMAPTMTORJAK2TRPV1
SCHEMBL2846471 0.90 TNK2 (0.43) SYKMAPTMTORJAK2TRPV1
SCHEMBL2844912 0.89 MAPT (0.45) SYKMAPTMTORJAK2JAK3
SCHEMBL2448060 0.85 TRPV1 (0.40) SYKJAK2TRPV1MERTK
SCHEMBL2843651 0.84 MAPT (0.43) SYKMAPTMTORTRPV1RAF1
SCHEMBL2537540 0.84 TRPV1 (0.46) SYKMAPTTRPV1CCND3CCNK
SCHEMBL8904410 0.82 MAPT (0.47) SYKMAPTMTORJAK2JAK3
SCHEMBL2842254 0.82 MAPT (0.51) SYKMAPTMTORJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 SYK 641/4885MAPT 10/4885MTOR 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.